Mizuno Lab

Publications

Pavia, K; Girdwood, ST; Paice, K; Dong, M; Mizuno, T; Tang, P; Mangeot, C; Vinks, AA; Kaplan, J. Acute kidney injury is associated with abnormal cefepime exposure among critically ill children and young adults. Pediatric Nephrology. 2025; 40:513-521.

Masuda, S; Lemaitre, F; Barten, MJ; Bergan, S; Shipkova, M; van Gelder, T; Vinks, S; Wieland, E; Bornemann-Kolatzki, K; Brunet, M; Venkataramanan, R; Walson, P; Woillard, JB; Langman, LJ. Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring. 2025; 47:4-31.

Hambrick, HR; Punt, N; Pavia, K; Mizuno, T; Goldstein, SL; Tang Girdwood, S. Monte Carlo simulations of cefepime in children receiving continuous kidney replacement therapy support continuous infusions for target attainment. Journal of Intensive Care. 2024; 12:38.

Paice, K; Tang Girdwood, S; Mizuno, T; Pavia, K; Punt, N; Tang, P; Dong, M; Curry, C; Jones, R; Gibson, A; Vinks, AA; Kaplan, J. Pharmacokinetic Factors Associated With Early Meropenem Target Attainment in Pediatric Severe Sepsis. Pediatric Critical Care Medicine. 2024; 25:1103-1116.

Junior, RM; Mizuno, T; Paice, KM; Pavia, KE; Rhodes Hambrick, H; Tang, P; Jones, R; Gibson, A; Stoneman, E; Curry, C; Kaplan, J; Girdwood, ST. Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation. Journal of Antimicrobial Chemotherapy. 2024; 79:2668-2677.

Morales, R; Mizuno, T; Paice, KM; Hambrick, HR; Punt, N; Tang Girdwood, S. Impact of fluid balance on beta-lactam antibiotics target attainment: Insights from a simulation-based meropenem study. International Journal of Antimicrobial Agents. 2024; 64:107267.

Power-Hays, A; Dong, M; Punt, N; Mizuno, T; Smart, LR; Vinks, AA; Ware, RE. Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia. Clinical Pharmacology and Therapeutics. 2024; 116:670-677.

Minichmayr, IK; Mizuno, T; Goswami, S; Peck, RW; Polasek, TM. Recent Advances Addressing the Challenges of Precision Dosing. Clinical Pharmacology and Therapeutics. 2024; 116:527-530.

Wilson, NK; Tremblay, S; Shields, AR; Woodle, ES; Alloway, RR; Vinks, AA; Miyagawa, B; Mizuno, T. Belatacept Removal by Plasmapheresis: Dose Adjustments and Clinical Recommendations. Transplantation Direct. 2024; 10:e1677.

van Hoogdalem, MW; Tanaka, R; Johnson, TN; Vinks, AA; Mizuno, T. Development and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear Bioavailability. Drug metabolism and disposition: the biological fate of chemicals. 2024; 52:785-796.

Alsoud, D; Moes, DJ A R; Wang, Z; Soenen, R; Layegh, Z; Barclay, M; Mizuno, T; Minichmayr, IK; Keizer, RJ; Wicha, SG; De Vries, A; Papamichael, K; Padullés-Zamora, N; Dreesen, E. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring. 2024; 46:291-308.

Capal, JK; Ritter, DM; Franz, DN; Griffith, M; Currans, K; Kent, B; Bebin, EM; Northrup, H; Koenig, MK; Mizuno, T; Greiner, HM; Holland-Bouley, K; Horn, PS; Krueger, DA. Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results. 2024; 2:106-119.

Hambrick, HR; Fei, L; Pavia, K; Kaplan, J; Mizuno, T; Tang, P; Schuler, E; Benoit, S; Girdwood, ST. Cystatin C Outperforms Creatinine in Predicting Cefepime Clearance in Pediatric Stem Cell Transplant Recipients. Transplantation and Cellular Therapy. 2024; 30:614.e1-614.e11.

Nasr, A; Mizuno, T; Irie, K; Dillman, J; Jackson, K; Lynch, K; Horrell, A; Chun, KY; Yang, JM; Hyams, JS; Boyle, BM; Noe, JD; Denson, LA; Minar, PP. 958 ATTAINING EARLY ANTI-TNF EXPOSURE TARGETS IS ASSOCIATED WITH IMPROVED RATES OF ENDOSCOPIC HEALING AND TRANSMURAL HEALING IN CHILDREN WITH CROHN'S DISEASE. Gastroenterology. 2024; 166:s-226-s-227.

Yamashita, Y; Hira, D; Morita, M; Katsube, Y; Takakura, M; Tomotaki, H; Tomotaki, S; Xiong, W; Shiomi, H; Horie, T; Ueshima, S; Mizuno, T; Terada, T; Ono, K. Potential treatment option of rivaroxaban for breastfeeding women: A case series. Thrombosis Research. 2024; 237:141-144.

Strawn, JR; Poweleit, EA; Taylor, ZL; Mizuno, T; Vaughn, S; Desta, Z; Stancil, S; Ramsey, LB. 84 Using Opportunistic Sampling and Remnant Blood Samples to Develop Pediatric Pharmacokinetic Models to Inform Antidepressant Dosing. Journal of Clinical and Translational Science. 2024; 8:22-23.

Hambrick, HR; Cervantes, F; Dong, M; Tang, P; Arbough, T; Vinks, AA; Mizuno, T; Goldstein, SL; Kaplan, J; Girdwood, ST. Ceftriaxone Pharmacokinetics and Pharmacodynamic Target Attainment for Three Pediatric Patients Receiving Continuous Kidney Replacement Therapy. Journal of Pediatric Pharmacology and Therapeutics. 2024; 29:180-187.

Minar, PP; Colman, RJ; Zhang, N; Mizuno, T; Vinks, AA. Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA. BMJ Open. 2024; 14:e077193.

van Hoogdalem, MW; Tanaka, R; Abduljalil, K; Johnson, TN; Wexelblatt, SL; Akinbi, HT; Vinks, AA; Mizuno, T. Forecasting Fetal Buprenorphine Exposure through Maternal-Fetal Physiologically Based Pharmacokinetic Modeling. Pharmaceutics. 2024; 16:375.

Shimamoto, Y; Fukushima, K; Mizuno, T; Ichikawa, H; Kurosaki, K; Maeda, S; Okuda, M. Model-Informed Vancomycin Dosing Optimization to Address Delayed Renal Maturation in Infants and Young Children with Critical Congenital Heart Disease. Clinical Pharmacology and Therapeutics. 2024; 115:239-247.

Sagcal-Gironella, AC P; Merritt, A; Mizuno, T; Dharnidharka, VR; McDonald, J; DeGuzman, M; Wahezi, D; Goilav, B; Onel, K; Kim, S; Hersh, A; Huang, B; Devarajan, P; Brunner, H. Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis-A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study). Journal of Clinical Trials. 2024; 14:563.

Paice, K; Tang Girdwood, S; Pavia, K; Mizuno, T; Kaplan, J. 868: EARLY MEROPENEM CLEARANCE OF CRITICALLY ILL PATIENTS IN A PEDIATRIC INTENSIVE CARE UNIT. Critical Care Medicine. 2024; 52:s407.

Taylor, ZL; Poweleit, EA; Paice, K; Somers, KM; Pavia, K; Vinks, AA; Punt, N; Mizuno, T; Girdwood, ST. Tutorial on model selection and validation of model input into precision dosing software for model-informed precision dosing. CPT: Pharmacometrics and Systems Pharmacology. 2023; 12:1827-1845.

Cervantes, FC; Mizuno, T; Dong, M; Tang, P; Arbough, T; Vinks, AA; Kaplan, JM; Girdwood, SC T. Ceftriaxone Pharmacokinetics and Pharmacodynamics in 2 Pediatric Patients on Extracorporeal Membrane Oxygenation Therapy. Therapeutic Drug Monitoring. 2023; 45:832-836.

Poweleit, EA; Taylor, ZL; Mizuno, T; Vaughn, SE; Desta, Z; Strawn, JR; Ramsey, LB. Escitalopram and Sertraline Population Pharmacokinetic Analysis in Pediatric Patients. Clinical Pharmacokinetics. 2023; 62:1621-1637.

Alghamdi, A; Seay, S; Hooper, DK; Varnell, CD; Darland, L; Mizuno, T; Lazear, D; Ramsey, LB. Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients. Clinical and Translational Science. 2023; 16:1768-1778.

Pavia, K; Hambrick, HR; Paice, K; Tang, P; Punt, N; Kaplan, J; Goldstein, SL; Vinks, AA; Mizuno, T; Tang Girdwood, S. Cefepime pharmacokinetics in critically ill children and young adults undergoing continuous kidney replacement therapy. Journal of Antimicrobial Chemotherapy. 2023; 78:2140-2147.

Colman, RJ; Samuels, A; Mizuno, T; Punt, N; Vinks, AA; Minar, P. Model-informed Precision Dosing for Biologics Is Now Available at the Bedside for Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2023; 29:1342-1346.

Miyagawa, B; Lazear, D; Hooper, DK; Vinks, AA; Mizuno, T. Model-Informed Estimation of Acutely Decreased Tacrolimus Clearance and Subsequent Dose Individualization in a Pediatric Renal Transplant Patient With Posterior Reversible Encephalopathy Syndrome. Therapeutic Drug Monitoring. 2023; 45:376-382.

Samuels, A; Punt, N; Mizuno, T; Vinks, AA; Minar, PP. 347 DISEASE PROGRESSION PHARMACOKINETIC MODELING IMPROVES THE ACCURACY OF EARLY INFLIXIMAB CONCENTRATION TARGETS. Gastroenterology. 2023; 164:s-59.

Whaley, KG; Xiong, Y; Karns, R; Hyams, JS; Kugathasan, S; Boyle, BM; Walters, TD; Kelsen, J; LeLeiko, N; Shapiro, J; D'Haens, GR; Denson, LA; Vinks, AA; Rosen, MJ. Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2023; 21:1338-1347.

Rosen, MJ; Rabizadeh, S; Panetta, JC; Mizuno, T; Vinks, AA; Whaley, KG; Hyams, JS; Kugathasan, S; Boyle, BM; Walters, TD; Kelsen, JR; Leleiko, NS; Shapiro, JM; Dervieux, T. 714 INFLIXIMAB CLEARANCE IN RELATION TO DISEASE ACTIVITY DURING INDUCTION AND MAINTENANCE THERAPY OF ACUTE SEVERE AND AMBULATORY PEDIATRIC ULCERATIVE COLITIS. Gastroenterology. 2023; 164:s-150.

Poweleit, EA; Vinks, AA; Mizuno, T. Artificial Intelligence and Machine Learning Approaches to Facilitate Therapeutic Drug Management and Model-Informed Precision Dosing. Therapeutic Drug Monitoring. 2023; 45:143-150.

Colman, RJ; Mizuno, T; Fukushima, K; Haslam, DB; Hyams, JS; Boyle, B; Noe, JD; D'Haens, GR; Van Limbergen, J; Chun, K; Yang, J; Denson, LA; Ollberding, NJ; Vinks, AA; Minar, P. Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance. Alimentary Pharmacology and Therapeutics. 2023; 57:524-539.

Pavia, K; Girdwood, ST; Paice, K; Jones, R; Curry, C; Stoneman, E; Yunger, T; Gamel, N; Gibson, A; Dong, M; Tang, P; Mizuno, T; Vinks, A; Kaplan, J. 610: RENAL IMPAIRMENT IS ASSOCIATED WITH HIGH CEFEPIME CONCENTRATIONS IN CRITICALLY ILL CHILDREN. Critical Care Medicine. 2023; 51:294.

Paice, K; Girdwood, ST; Pavia, K; Mizuno, T; Tang, P; Curry, C; Gibson, A; Jones, R; Stoneman, E; Yunger, T; Dong, M; Vinks, A; Kaplan, J. 38: CRITICALLY ILL CHILDREN WITH SEVERE SEPSIS OFTEN HAVE SUB-TARGET MEROPENEM LEVELS EARLY IN THERAPY. Critical Care Medicine. 2023; 51:19.

Caldwell, J; Lazear, D; Miyagawa, B; Mizuno, T; Quinn, CT; Stone, H; Hooper, DK; Varnell, CD. Pharmacokinetic-Guided Dosing to Maintain Therapeutic Tacrolimus Levels During Post-Kidney Transplant Erythrocytapheresis in a Patient With Sickle Cell Anemia. Journal of the American Society of Nephrology : JASN. 2022; 33:840.

Hirabatake, M; Mizuno, T; Kato, H; Hashida, T. Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer. Frontiers in Pharmacology. 2022; 13:984002.

van Hoogdalem, MW; Wexelblatt, SL; Akinbi, HT; Vinks, AA; Mizuno, T. A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome. Pharmacology and Therapeutics. 2022; 234:108045.

Mizuno, T; Dong, M; Taylor, ZL; Ramsey, LB; Vinks, AA. Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care. British Journal of Clinical Pharmacology. 2022; 88:1418-1426.

Colman, RJ; Xiong, Y; Mizuno, T; Hyams, JS; Noe, JD; Boyle, B; D’Haens, GR; van Limbergen, J; Chun, K; Yang, J; Rosen, MJ; Denson, LA; Vinks, A; Minar, P. Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease. Alimentary Pharmacology and Therapeutics. 2022; 55:593-603.

Minar, P; Samuels, A; Mizuno, T; Menke, F; Vogt, A; Punt, N; Vinks, A. BIOLOGIC PRECISION DOSING IS NOW AVAILABLE AT THE BEDSIDE FOR CHILDREN AND ADULTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB. Gastroenterology. 2022; 162:s98-s99.

van Hoogdalem, MW; Johnson, TN; McPhail, BT; Kamatkar, S; Wexelblatt, SL; Ward, LP; Christians, U; Akinbi, HT; Vinks, AA; Mizuno, T. Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome. Clinical Pharmacology and Therapeutics. 2022; 111:496-508.

Samuels, A; Punt, N; Reifenberg, J; Mizuno, T; Colman, R; Menke, F; Vogt, A; Vinks, A; Minar, P. PREDICTIVE PERFORMANCE OF DIFFERENT POPULATION PHARMACOKINETIC MODELS IN A REAL-WORLD COHORT OF CROHN’S DISEASE PATIENTS. Gastroenterology. 2022; 162:s99-s100.

Colman, R; Mizuno, T; Hyams, J; Noe, J; Boyle, B; Denson, L; Vinks, A; Minar, P. REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY IN CHILDREN IDENTIFIES TWO NOVEL BIOMARKERS OF DRUG CLEARANCE. Gastroenterology. 2022; 162:s100.

Samuels, A; Punt, N; Reifenberg, J; Mizuno, T; Colman, R; Menke, F; Vogt, A; Vinks, A; Minar, P. PREDICTIVE PERFORMANCE OF DIFFERENT POPULATION PHARMACOKINETIC MODELS IN A REAL-WORLD COHORT OF CROHN’S DISEASE PATIENTS. Inflammatory Bowel Diseases. 2022; 28:s99-s100.

Colman, R; Mizuno, T; Hyams, J; Noe, J; Boyle, B; Denson, L; Vinks, A; Minar, P. REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY IN CHILDREN IDENTIFIES TWO NOVEL BIOMARKERS OF DRUG CLEARANCE. Inflammatory Bowel Diseases. 2022; 28:s100.

Minar, P; Samuels, A; Mizuno, T; Menke, F; Vogt, A; Punt, N; Vinks, A. BIOLOGIC PRECISION DOSING IS NOW AVAILABLE AT THE BEDSIDE FOR CHILDREN AND ADULTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB. Inflammatory Bowel Diseases. 2022; 28:s98-s99.

Taylor, ZL; Thompson, LE; Bear, H; Mizuno, T; Vinks, AA; Ramsey, LB. Toward pharmacogenetic SLCO1B1-guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model. Clinical and Translational Science. 2021; 14:2267-2277.

Shimamoto, Y; Verstegen, RH J; Mizuno, T; Schechter, T; Allen, U; Ito, S. Population pharmacokinetics of vancomycin in paediatric patients with febrile neutropenia and augmented renal clearance: development of new dosing recommendations. Journal of Antimicrobial Chemotherapy. 2021; 76:2932-2940.

Xiong, Y; Mizuno, T; Colman, R; Hyams, J; Noe, JD; Boyle, B; Tsai, YT; Dong, M; Jackson, K; Punt, N; Rosen, MJ; Denson, LA; Vinks, AA; Minar, P. Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Clinical Pharmacology and Therapeutics. 2021; 109:1639-1647.

Bergan, S; Brunet, M; Hesselink, DA; Johnson-Davis, KL; Kunicki, PK; Lemaitre, F; Marquet, P; Molinaro, M; Noceti, O; Pattanaik, S; Vinks, AA; Wallemacq, P; Åsberg, A; Langman, LJ. Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring. 2021; 43:150-200.

Sebold, AJ; Day, AM; Ewen, J; Adamek, J; Byars, A; Cohen, B; Kossoff, EH; Mizuno, T; Ryan, M; Sievers, J; Vinks, A; Zabel, TA; Hammill, AM; Comi, AM. Sirolimus Treatment in Sturge-Weber Syndrome. Pediatric Neurology. 2021; 115:29-40.

Wright, KD; Yao, X; London, WB; Kao, PC; Gore, L; Hunger, S; Geyer, R; Cohen, KJ; Allen, JC; Katzenstein, HM; Vinks, AA; Prabhu, SP; Chi, SN; Kieran, MW. A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. Pediatric Blood and Cancer. 2021; 68:e28787.

Mizuno, T; McPhail, BT; Kamatkar, S; Wexelblatt, S; Ward, L; Christians, U; Akinbi, HT; Vinks, AA. Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome. Clinical Pharmacokinetics. 2021; 60:249-259.

van Hoogdalem, MW; McPhail, BT; Hahn, D; Wexelblatt, SL; Akinbi, HT; Vinks, AA; Mizuno, T. Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics. Expert Opinion on Drug Metabolism and Toxicology. 2021; 17:87-103.